In vitro exposure to clofazimine can select for delamanid and pretomanid resistance in Mycobacterium tuberculosis
Antimicrobial Agents and Chemotherapy · 2025
DOI: 10.1128/aac.01113-25 ↗Kurz gefasst
Fachartikel in der Zeitschrift Antimicrobial Agents and Chemotherapy, 2025. Verfasst von Praharshinie Rupasinghe und 15 weiteren Autor:innen. Beteiligte Einrichtung: Unit of Mycobacteriology, Department of Biomedical Sciences, Institute of Tropical Medicine, Antwerp, Belgium. Hauptthemen laut MEDLINE: Nitroimidazoles, Clofazimine, Mycobacterium tuberculosis, Antitubercular Agents. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 25 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
In vitro experiments with Mycobacterium tuberculosis showed that clofazimine exposure selected for delamanid and pretomanid resistance and mutations in fbiA , fbiC , or fbiD —after the acquisition of Rv0678 mutations where this could be determined. Whether this is also possible in vivo and in an Rv0678 wild-type background has to be studied further. Based on the available evidence, however, we propose that nitroimidazole resistance should not be considered an exclusion criterion for the use of clofazimine.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Unit of Mycobacteriology, Department of Biomedical Sciences, Institute of Tropical Medicine, Antwerp, Belgium.
- Belgian Coordinated Collections of Microorganisms - Mycobacterial collection (BCCM-ITM), Antwerp, Belgium.
- South African Medical Research Council Centre for Tuberculosis Research, Division of Molecular Biology and Human Genetics, Faculty of Medicine and Health Sciences, Stellenbosch University, Cape Town, South Africa.
- Centre for Tuberculosis, National Institute for Communicable Diseases, a division of the National Health Laboratory Services, Johannesburg, South Africa.
- Emerging Bacterial Pathogens Unit, IRCCS San Raffaele Scientific Institute, Milan, Italy.
- Department of Biomedical and Clinical Sciences, Division of Infection and Inflammation, Linkoping University, Linköping, Sweden.
ORCID-Profile: Praharshinie Rupasinghe, Nabila Ismail, Wim Mulders, Robin M Warren, Lavania Joseph, Dumisani Ngcamu, Thabisile Gwala, Shaheed V Omar, Jens Vereecken, Bouke C de Jong, Leen Rigouts, Emanuele Borroni, Daniela M Cirillo, Paolo Miotto, Claudio U Köser
Zitieren
APA
Rupasinghe, P., Ismail, N., Mulders, W., Warren, R. M., Joseph, L., Ngcamu, D., Gwala, T., Omar, S. V., Vereecken, J., de Jong, B. C., Rigouts, L., Borroni, E., Cirillo, D. M., Schön, T., Miotto, P., & Köser, C. U. (2025). In vitro exposure to clofazimine can select for delamanid and pretomanid resistance in Mycobacterium tuberculosis. Antimicrobial Agents and Chemotherapy. https://doi.org/10.1128/aac.01113-25
Vancouver
Rupasinghe P, Ismail N, Mulders W, Warren RM, Joseph L, Ngcamu D, et al. In vitro exposure to clofazimine can select for delamanid and pretomanid resistance in Mycobacterium tuberculosis. Antimicrobial Agents and Chemotherapy. 2025. doi:10.1128/aac.01113-25
BibTeX
@article{Rupasinghe2025,
author = {Rupasinghe, Praharshinie and Ismail, Nabila and Mulders, Wim and Warren, Robin M and Joseph, Lavania and Ngcamu, Dumisani and Gwala, Thabisile and Omar, Shaheed V and Vereecken, Jens and de Jong, Bouke C and Rigouts, Leen and Borroni, Emanuele and Cirillo, Daniela M and Schön, Thomas and Miotto, Paolo and Köser, Claudio U},
title = {In vitro exposure to clofazimine can select for delamanid and pretomanid resistance in Mycobacterium tuberculosis},
journal = {Antimicrobial Agents and Chemotherapy},
year = {2025},
doi = {10.1128/aac.01113-25}
}
EUVIMED